Cargando…
Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer’s disease
BACKGROUND: Familial Alzheimer’s disease (FAD) is caused by mutations in the amyloid precursor protein (APP) or presenilin (PS). Most PS mutations, which account for the majority of FAD cases, lead to an increased ratio of longer to shorter forms of the amyloid beta (Aβ) peptide. The therapeutic rat...
Autores principales: | Blain, Jean-François, Bursavich, Matthew G., Freeman, Emily A., Hrdlicka, Lori A., Hodgdon, Hilliary E., Chen, Ting, Costa, Don E., Harrison, Bryce A., Kapadnis, Sudarshan, Murphy, Deirdre A., Nolan, Scott, Tu, Zhiming, Tang, Cuyue, Burnett, Duane A., Patzke, Holger, Koenig, Gerhard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5004293/ https://www.ncbi.nlm.nih.gov/pubmed/27572246 http://dx.doi.org/10.1186/s13195-016-0199-5 |
Ejemplares similares
-
Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice
por: Rogers, Kathryn, et al.
Publicado: (2012) -
The safety concept of the FRM-II
por: Axmann, A, et al.
Publicado: (2003) -
Identification of an operon involved in fluoride resistance in Enterobacter cloacae FRM
por: Liu, Xiaoqing, et al.
Publicado: (2017) -
Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency: A Randomized Clinical Trial
por: Ljubenkov, Peter A., et al.
Publicado: (2021) -
Financial Risk Manager Handbook + Test Bank: FRM Part I / Part II
por: Jorion, Philippe
Publicado: (2010)